Drug Trial Radar · NCT07116889
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
Last checked: Nov 19, 2026Latest source record: Nov 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
Dec 12, 2023
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Generate BiomedicinesIndustry
- Sponsor type
- Industry
- First posted
- Aug 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.
Conditions
- Asthma
- COPD (Chronic Obstructive Pulmonary Disease)
Interventions
GB-0895 (SC)Biological
Single subcutaneous dose of GB-0895
GB-0895 (SC)Biological
Multiple subcutaneous doses of GB-0895
Placebo (SC)Drug
Single subcutaneous dose of placebo
Placebo (SC)Drug
Multiple subcutaneous doses of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment related adverse events as assessed by CTCAE 5.0Time frame: Day 1 to Day 500
Locations
13 sites in 3 countries. Site status is shown where the registry gives one.
Alcanza
DeLand, Florida
Miami Research Institute of South Florida
Miami, Florida
Omega Research
Orlando, Florida
Nucleus Network
Saint Paul, Minnesota
Southeastern Research Center
Winston-Salem, North Carolina
DM Clinical Research
Tomball, Texas
Charite Research Organization GmbH
Berlin, Germany
IKF Pneumologie
Frankfurt, Germany
Fraunhofer Institut fur Toxikologie and Experimentelle Medizin (ITEM)
Hanover, Germany
Hammersmith Medicines Research
London, United Kingdom
Queen Anne Street Medical Center
London, United Kingdom
Medicines Evaluation Unit (MEU)
Manchester, United Kingdom
Simbec-Orion Clinical Development
Merthyr Tydfil, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.